MX2016005687A - Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta. - Google Patents
Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta.Info
- Publication number
- MX2016005687A MX2016005687A MX2016005687A MX2016005687A MX2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- binding polypeptide
- immunosuppressive therapy
- humanized
- alpha beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción está relacionada con métodos mejorados para uso de un polipéptido de unión humanizado específico para el receptor de linfocitos T alfa beta (aß-TCR). En particular, esta descripción está relacionada con métodos mejorados de uso de un anticuerpo anti-aß-TCR humanizado, que deriva del anticuerpo monoclonal murino BMA031, en terapia inmunosupresora. También se proporcionan métodos nuevos usando anticuerpos monoclonales humanizados y/o fragmentos de anticuerpo monoclonal humanizado (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos). Se proporcionan métodos nuevos que usan administración repetida de anticuerpos monoclonales humanizados y/o fragmentos de anticuerpos monoclonales humanizados (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos) para reducir linfocitos T aß en el sujeto en relación con linfocitos T yd en el sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361897809P | 2013-10-30 | 2013-10-30 | |
PCT/US2014/063254 WO2015066379A2 (en) | 2013-10-30 | 2014-10-30 | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005687A true MX2016005687A (es) | 2017-03-30 |
Family
ID=52021413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005687A MX2016005687A (es) | 2013-10-30 | 2014-10-30 | Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta. |
Country Status (8)
Country | Link |
---|---|
US (2) | US11142575B2 (es) |
EP (1) | EP3063174B1 (es) |
CN (1) | CN106795220A (es) |
AU (2) | AU2014342182B2 (es) |
CA (1) | CA2928756A1 (es) |
MX (1) | MX2016005687A (es) |
SG (2) | SG10201803473WA (es) |
WO (1) | WO2015066379A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015066379A2 (en) * | 2013-10-30 | 2015-05-07 | Genzyme Corporation | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
US20180298099A1 (en) * | 2015-09-16 | 2018-10-18 | Harry C. Ledebur, Jr. | T-Cell Recepter (TCR) Targeting Therapies for Immune-Mediated Adverse Drug Reactions (ADRs) and Other Conditions |
CN108070644B (zh) * | 2016-11-08 | 2021-06-29 | 国家卫生计生委科学技术研究所 | 一种妊娠高血压的诊断系统 |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
BR112020000273A2 (pt) * | 2017-07-07 | 2020-07-14 | Hanmi Pharm. Co., Ltd. | proteína de fusão de enzima e seu método de preparação, composição farmacêutica, polinucleotídeo que codifica a proteína de fusão de enzima, vetor de expressão, transformante |
CN109777778B (zh) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | 一种基因改造的γδT细胞 |
DE102017127984B4 (de) * | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
EP3947458A1 (en) * | 2019-04-03 | 2022-02-09 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
CA3160997A1 (en) * | 2019-11-14 | 2021-05-20 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
CN116234829A (zh) * | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20050058641A1 (en) | 2002-05-22 | 2005-03-17 | Siemionow Maria Z. | Tolerance induction and maintenance in hematopoietic stem cell allografts |
EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
AU2007345745C1 (en) | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
GEP20125693B (en) | 2007-01-09 | 2012-11-26 | Biogen Idec Inc | Sp35 antibodies and usage thereof |
WO2010027797A1 (en) | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9018006B2 (en) * | 2010-07-23 | 2015-04-28 | The University Of Toledo | Stable Tregs and related materials and methods |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
WO2015066379A2 (en) * | 2013-10-30 | 2015-05-07 | Genzyme Corporation | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
-
2014
- 2014-10-30 WO PCT/US2014/063254 patent/WO2015066379A2/en active Application Filing
- 2014-10-30 AU AU2014342182A patent/AU2014342182B2/en not_active Ceased
- 2014-10-30 MX MX2016005687A patent/MX2016005687A/es unknown
- 2014-10-30 SG SG10201803473WA patent/SG10201803473WA/en unknown
- 2014-10-30 CN CN201480071641.4A patent/CN106795220A/zh active Pending
- 2014-10-30 CA CA2928756A patent/CA2928756A1/en not_active Abandoned
- 2014-10-30 US US15/029,770 patent/US11142575B2/en active Active
- 2014-10-30 SG SG11201603193PA patent/SG11201603193PA/en unknown
- 2014-10-30 EP EP14810045.6A patent/EP3063174B1/en active Active
-
2020
- 2020-08-12 AU AU2020217395A patent/AU2020217395A1/en not_active Abandoned
-
2021
- 2021-09-08 US US17/469,179 patent/US20220098299A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015066379A3 (en) | 2015-07-09 |
US11142575B2 (en) | 2021-10-12 |
SG10201803473WA (en) | 2018-06-28 |
SG11201603193PA (en) | 2016-05-30 |
US20160244523A1 (en) | 2016-08-25 |
AU2014342182A1 (en) | 2016-05-19 |
AU2014342182B2 (en) | 2020-05-14 |
CA2928756A1 (en) | 2015-05-07 |
EP3063174A2 (en) | 2016-09-07 |
AU2020217395A1 (en) | 2020-09-03 |
EP3063174B1 (en) | 2020-12-09 |
US20220098299A1 (en) | 2022-03-31 |
CN106795220A (zh) | 2017-05-31 |
WO2015066379A2 (en) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016005687A (es) | Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta. | |
PH12018500766A1 (en) | Bispecific antibodies with tetravalency for a costimulatory tnf receptor | |
MX2020011744A (es) | Molecula de polipeptido con especificidad dual mejorada. | |
MX2023006482A (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. | |
PH12020500368A1 (en) | B7-h4 antibodies and methods of use thereof | |
MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MX2020003046A (es) | Anticuerpos anti-hla-a2 y metodos para utilizar los mismos. | |
WO2014011988A3 (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
MX2021013336A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
MX2015014017A (es) | Variante de la region fc. | |
MX2017012805A (es) | Complejo de unión a antígenos con actividad agonista y métodos de uso. | |
WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
MX2015008740A (es) | Variantes de regiones fc de igg1 de humano y usos de las mismas. | |
NZ628314A (en) | Cd47 antibodies and methods of use thereof | |
MX357193B (es) | Moleculas de union anti-alfa sinucleina. | |
TR201903312T4 (tr) | Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. | |
NZ760841A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
MX343659B (es) | Proteínas de unión receptoras fc. | |
MX2015003150A (es) | Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos. | |
MX2016005765A (es) | Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos. | |
UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof |